Evolve DD — June 3, 2026
2026-06-03 19:16 · 9.8 KB
Type: Deep Evolution Round
Date: 2026-06-03
Stocks Updated: Resonac (4004.T), Tokyo Ohka Kogyo (4186.T), M3 Inc (2413.T)
Previous Evolve: 2026-06-02
Overview
Three stocks from the oldest data tranche (April 14–15, 2026, ~7 weeks stale) were selected for deep evolution. All three are in AI-adjacent or healthcare themes with MEDIUM conviction.
| Ticker | Name | Theme | Old Date | Status |
|---|---|---|---|---|
| 4004.T | Resonac Holdings | AI/GPU Supply Chain | 2026-04-15 | HOLD |
| 4186.T | Tokyo Ohka Kogyo | AI/GPU Supply Chain | 2026-04-15 | HOLD |
| 2413.T | M3, Inc. | Healthcare | 2026-04-14 | HOLD |
4004.T — Resonac Holdings Corporation
Thesis Update: HOLD
Turnaround confirmed. The April thesis asked whether the 84.1x PE was justified by an emerging margin recovery. It is. FY2026 NI guidance of ¥77B (2.7x prior year) and Q1 FY2026 EBITDA margin of 18.2% — approaching the company's 20% target — validate the turnaround. The stock rallied from ~¥13,000 (April 2026) to an ATH of ¥20,495 on May 14, then pulled back to ¥17,200.
Key financial changes:
| Metric | Old (Apr 2026) | New (Jun 2026) | Source |
|---|---|---|---|
| PE | 84.1x (trailing) | ~40x forward | Calculated: ¥3.11T / ¥77B NI guidance |
| Op Margin | 3.5% | 18.2% EBITDA (Q1) | Resonac Q1 FY2026 results |
| Market Cap | N/A | ¥3.11T | TradingEconomics / cbonds |
| ROE | 4.0% | ~8.5% est. | Derived from NI guidance |
| Key Dates | None | 4 added | Resonac IR |
Q1 FY2026 (Jan–Mar 2026):
- Revenue ¥307.9B (missed estimate -6.67%, geopolitical timing)
- Core OP ¥33.6B (+2.3x YoY) — back-end AI materials at quarterly record
- EBITDA margin 18.2% (+6.2pp YoY), ex-Cluster Chemicals 21.6% (above 20% target)
- Semiconductor segment: Revenue +21% to ¥134.7B, Core OP +74% to ¥34B
H1 FY2026 guidance raised:
- Revenue: ¥660B (+7% vs initial)
- Core OP: ¥74B (+40% vs initial)
- Full-year maintained at ¥1.23T / ¥105B core OP (Middle East uncertainty cited)
Supply Chain: All relationships verified. TSMC "2025 Excellent Performance Award" for advanced packaging materials and high-purity gas confirmed at TSMC Supply Chain Forum Dec 2025. TSMC Kumamoto local production active. JOINT3 consortium (27 members, Applied Materials, TEL) developing panel-level interposers.
Risk Flags
- AP01 AMBER: FY2025 semiconductor materials OP was record ¥109.1B (+47%). Not a classic cyclical peak (AI is structural), but monitor for demand normalization.
- PRICE RISK: Stock ¥17,200 trades 21% ABOVE analyst consensus target ¥14,243. Elevated near-term reversion risk.
- PB GUARDRAIL TRIGGERED: PB ~3.4x exceeds materials sector 80th percentile (~3x). Override: turnaround PE compression justifies structural premium.
- FCF GUARDRAIL TRIGGERED: FCF growth far exceeds 15% as core OP grew 2.3x. Override: AI semiconductor materials structural demand justifies above-15% FCF growth for 2–3 years.
- REVENUE MISS: Q1 revenue missed estimates by 6.67%. Watch H2 for recovery.
Inversion: Thesis breaks if AI server capex growth slows >30% or back-end materials revenue declines two consecutive quarters.
4186.T — Tokyo Ohka Kogyo (TOK)
Thesis Update: HOLD (with anti-pattern flags)
Thesis accelerating but with capacity expansion risk emerging. Q1 FY2026 was exceptional: revenue +23.6% YoY (¥67.1B), OP +53.8% (¥15.0B), NI +55.8% (¥11.7B). AI-related photoresist demand (Electronics Functional Materials +29%, High-Purity Chemicals +17.2%) drove the beat.
Key financial changes:
| Metric | Old (Apr 2026) | New (Jun 2026) | Source |
|---|---|---|---|
| PE | 34.7x | 31.3x | SimplyWallSt Jun 2026 |
| ROE | 13.8% | 15.6% | FY2025 results |
| Op Margin | 20.0% | 20.5% (Q1) | Q1 tanshin |
| Div Yield | N/A | 0.7% | ¥80/share FY2026 |
| Market Cap | N/A | ~¥1T | Web research |
| Key Dates | None | 4 added | TOK IR, TrendForce |
FY2026 full-year guidance (maintained at Q1):
- Revenue ¥261.0B (+10.1%)
- OP ¥52.2B (+10.2%)
- Note: guidance conservative vs Q1 run-rate of +23.6%; either caution or genuine H2 slowdown expected.
Supply Chain:
- TSMC (confirmed): EUV/ArF/KrF photoresists, mass production lines. Source: TrendForce Nov 2025.
- Samsung Electronics (confirmed): Korea plant ¥20B to serve Samsung/SK Hynix, operations 2030. Source: Digitimes Dec 2025.
- SK Hynix (confirmed): Korea plant specifically targets HBM/advanced memory.
- Intel (confirmed): sub-2nm joint development agreement. Source: TrendForce Nov 2025.
Risk Flags
- AP02 TRIGGERED — Capacity Expansion Hangover: 4+ photoresist makers expanding simultaneously:
1. TOK: Koriyama Plant new building (2H 2026 start)
2. JSR: MOR production Korea (end-2026 start)
3. FUJIFILM: Entering EUV resist race
4. Sumitomo Chemical: Entering
This is the anti-pattern definition. Hangover risk window: 2028–2030.
- AP01 FLAG — Record Earnings: FY2025 revenue ¥237B (+17.9%), OP ¥47.4B (+43.2%) were records. Q1 FY2026 is further above prior year. Cyclical peak proximity rising.
- PB GUARDRAIL TRIGGERED: PB 5.09x significantly above materials sector 80th percentile. Override: 15.6% ROE and 20%+ op margin justify premium, but monitor.
- EXPORT CONTROL RISK: Japan rumoured to curb photoresist exports (TrendForce Dec 2025). If enacted, China TAM immediately reduced.
Inversion: Thesis breaks if (a) photoresist ASPs decline >15% within 2 years of competitor plant startups, OR (b) Japan enacts material export controls restricting China sales.
2413.T — M3, Inc.
Thesis Update: HOLD (entry-point thesis confirmed)
Re-acceleration confirmed — stock cheaper than April. The April thesis said "-84% from peak creates entry point." FY2026 results delivered: revenue +23.3% to ¥351.4B, OP +16.8% to ¥73.5B. Forward PE fell from 23.6x (April thesis) to 17.9x — the stock is CHEAPER despite positive results.
Key financial changes:
| Metric | Old (Apr 2026) | New (Jun 2026) | Source |
|---|---|---|---|
| PE | 19.1x | 19.4x | Calculated ¥950B / ¥49.1B |
| Forward PE | 23.6x | 17.9x | Calculated ¥950B / ¥53B guided NI |
| PB | 2.55x | 2.4x | Estimated |
| Op Margin | 23.6% | 20.9% | FY2026: 73.5B / 351.4B |
| Market Cap | N/A | ¥950B | Web research |
| Key Dates | None | 4 added | M3 IR |
FY2026 results (year ended March 31, 2026):
- Revenue: ¥351.4B (+23.3% YoY)
- Operating profit: ¥73.5B (+16.8%)
- Net income: ¥49.1B (+21.3%)
- Dividend and capital return: raised with results announcement
FY2027 guidance:
- Revenue: ¥400.0B (+13.8%)
- Operating profit: ¥80.0B (+8.8%)
- Net income: ¥53.0B
Analyst consensus (June 2026): 9 buy, 0 sell; average 12-month target ¥2,299 — +56% upside from ¥1,474 current price.
Supply Chain: Stable. M3 platform serves global pharma (68% of revenue), Japanese hospitals/clinics, and hospice/nursing patients.
Risk Flags
- M&A Revenue Distortion: EWEL acquisition (April 2025) inflates Patient Solutions segment. Headline +23.3% vs organic ~12–15%. Monitor Medical Platform organic growth separately.
- Margin Dilution: Op margin 23.6% → 20.9% from hospice facility acquisitions. Physical care economics differ from digital platform.
- Deceleration Trend: FY2027 revenue guidance +13.8% vs FY2026 +23.3%. Growth slowing.
- Goldman Sachs Downgrade: Still on record from original thesis. Monitor for additional broker downgrades.
- All valuation guardrails CLEAR (forward PE 17.9x, PB 2.4x).
Inversion: Thesis breaks if Medical Platform organic growth (ex-M&A) falls below 8% for two consecutive quarters — signals doctor platform saturation, the core moat assumption.
Monitoring Summary
| Ticker | Next Key Date | Action Trigger |
|---|---|---|
| 4004.T | Aug 2026 (Q2 earnings) | Revenue recovery + EBITDA margin >20% → ADD. Sustained miss → TRIM |
| 4004.T | Stock at ¥13,000–14,000 | ADD to 9% (near analyst consensus, margin turnaround intact) |
| 4186.T | Aug 2026 (Q2 earnings) | If growth >20% continues → HOLD. If 2Q decelerates <10% → TRIM |
| 4186.T | Export control announcement | TRIM to 4% immediately |
| 2413.T | Aug 2026 (Q1 FY2027) | Medical Platform organic >12% → HOLD. Second broker downgrade → TRIM |
Sources
- Resonac Q1 FY2026 results (May 2026): https://finance.biggo.com/news/JP_4004.T_2026-05-13
- Resonac FY2026 NI forecast: https://finance.biggo.com/news/85LmVZwBEjg5DZ3vSKXy
- Resonac TSMC Award (Dec 2025): https://www.resonac.com/news/2025/12/01/3669.html
- TOK Q1 FY2026 (May 2026): https://www.theglobeandmail.com/investing/markets/stocks/TOKCF/pressreleases/1864524/
- TOK Korea plant (Dec 2025): https://www.digitimes.com/news/a20251216PD212/
- TOK FY2025 record results: https://www.investing.com/news/company-news/tokyo-ohka-kogyo-fy2025-slides-record-profits-surge-on-ai-chip-demand-93CH-4519251
- Japan photoresist capacity expansion (Nov 2025): https://www.trendforce.com/news/2025/11/06/news-japan-ramps-up-photoresist-investment-for-2nm-chips-tokyo-ohka-kogyo-jsr-lead-the-charge/
- Japan export control risk (Dec 2025): https://www.trendforce.com/news/2025/12/03/news-japan-rumored-to-curb-photoresist-exports-as-china-targets-40-self-sufficiency-by-2026/
- M3 FY2026 tanshin (May 1, 2026): https://corporate.m3.com/assets.ctfassets.net/1pwj74siywcy/6AXtFsK3kCFsZe3AxgoOJl/c035fee175e0eb6bcbb0d68233af5d73/20260501_FY25Q4_tanshin_E.pdf
- M3 FY2027 guidance (TipRanks): https://www.tipranks.com/news/company-announcements/m3-lifts-profit-21-and-hikes-dividend-as-it-targets-further-growth-in-fy2027
- M3 analyst consensus: search results, June 2026
*This report is for internal investment research purposes only. Not financial advice.*